Raymond James Financial Services Advisors Inc. Buys 5,515 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Raymond James Financial Services Advisors Inc. raised its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 47.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 17,252 shares of the company’s stock after purchasing an additional 5,515 shares during the quarter. Raymond James Financial Services Advisors Inc. owned 0.05% of TransMedics Group worth $1,362,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in TMDX. FMR LLC increased its holdings in shares of TransMedics Group by 42.5% during the 3rd quarter. FMR LLC now owns 4,714,870 shares of the company’s stock worth $258,139,000 after purchasing an additional 1,407,171 shares during the period. Eventide Asset Management LLC boosted its position in shares of TransMedics Group by 1,271.7% during the 3rd quarter. Eventide Asset Management LLC now owns 925,356 shares of the company’s stock valued at $50,663,000 after acquiring an additional 857,895 shares in the last quarter. Summit Partners Public Asset Management LLC boosted its position in shares of TransMedics Group by 71.9% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 957,282 shares of the company’s stock valued at $59,083,000 after acquiring an additional 400,255 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of TransMedics Group by 91.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock valued at $41,615,000 after acquiring an additional 363,012 shares in the last quarter. Finally, American Century Companies Inc. boosted its position in shares of TransMedics Group by 271.2% during the 3rd quarter. American Century Companies Inc. now owns 486,956 shares of the company’s stock valued at $26,661,000 after acquiring an additional 355,755 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Down 2.3 %

Shares of NASDAQ TMDX opened at $91.82 on Friday. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $99.63. The company has a market cap of $3.00 billion, a PE ratio of -119.25 and a beta of 1.99. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. The company has a 50-day moving average of $82.77 and a two-hundred day moving average of $72.03.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. The business had revenue of $81.20 million during the quarter, compared to the consensus estimate of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. TransMedics Group’s revenue for the quarter was up 158.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.21) earnings per share. As a group, equities analysts expect that TransMedics Group, Inc. will post -0.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TMDX has been the topic of several recent research reports. Morgan Stanley lifted their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. JPMorgan Chase & Co. boosted their price target on shares of TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Piper Sandler assumed coverage on shares of TransMedics Group in a research note on Thursday, March 28th. They issued an “overweight” rating and a $95.00 target price for the company. Finally, Oppenheimer boosted their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.00.

Insider Buying and Selling

In related news, CEO Waleed H. Hassanein sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the completion of the sale, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at $7,044,932.83. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, CEO Waleed H. Hassanein sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the completion of the sale, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at $7,044,932.83. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Tamer I. Khayal sold 15,512 shares of the business’s stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $90.45, for a total transaction of $1,403,060.40. Following the sale, the insider now directly owns 25,185 shares of the company’s stock, valued at $2,277,983.25. The disclosure for this sale can be found here. Insiders sold a total of 125,408 shares of company stock valued at $10,606,501 over the last ninety days. Insiders own 6.70% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.